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RegenerationThe osteogenic and osseointegrative potential of a smallmoleculewas examined to assess its usefulness in regen-
erative procedures. Purmorphaminewas used to stimulate bone growth and repair in an in vitro cell-based assay
and an in vivo chick embryo CAM-assaywith andwithout the presence of an implant. Purmorphamine adhered to
precipitated hydroxyapatite coating, could activate the sonic hedgehog pathway and thereby stimulated
osteodifferentiation. Porous calcium phosphate beads were used to deliver this small molecule in vivo and
showed that purmorphamine increased the trabecular bone to bone area signiﬁcantly. The assay showed
purmorphamine failed to induce any signiﬁcant difference in osseointegration on titanium coated PTFE implants.
This suggests that, while a small molecule can enhance osteogenesis and might be useful in regenerative proce-
dures, it failed to enhance the osseointegration of a Ti coated implant, suggesting that this sort of stimulation
might be useful for enhancing bone regeneration where bone loss due to disease exists, but not for enhancing
early stability of an implant.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Replacement of bone is an on-going challenge for surgeons in skeletal
and craniofacial restoration and applied scientists in bone engineering.
The need for dental or craniofacial restoration exists as bone loss in the
jaws often occurs due to disease or to the removal of large sections of
bone due to cancer or injury. There are currently two main approaches:
the use of autologous bone from elsewhere in the body (e.g. ﬁbula or iliac
crest) [1], or the use of implants e.g. titanium prostheses. In fact, the
approach required depends upon whether mechanical strength and
structure are needed, or whether the bone needs to be regenerated in a
non-load-bearing situation (e.g. alveolar bone loss). Tissue engineering
and regenerative medicine have sought to provide alternatives, with
only limited success, since the demands are very stringent—especially
where the synthetic tissue must possess mechanical strength.
Prostheses and implants restore excellent function when fully inte-
grated and are unlikely to be replaced by tissue engineered constructs;
however, there remains considerable room for improvement at the level
of integration [2]. Methods for the ﬁlling of defects have been lessc. Open access under CC BY-NC-ND lisuccessful as it has not been possible to trigger the required biological
response using hydroxyapatite, de-cellularized bone, or other packing
materials. Although these two approaches are very different, they
share the common element of needing to generate a new bone to
ﬁx or integrate an implant or to replace a resorbable matrix during
void ﬁlling. Failure of this bone generation leads to the formation of
ﬁbrous tissue due to movement at the bone–material interface of
an implant or due to failure of osteogenic differentiation in the
scaffold [3].
The aim of this research is to examine whether small molecules
which stimulate the hedgehog pathway can accelerate the formation
of bone and improve the integration of titanium implants [4].
Long bone fracture repair is mediated by a cartilaginous soft callus
that affects bony union through the stimulation of bone formation
around the callus and replacement of the cartilage itself by marrow and
bone tissue [5]. The same process of endochondral ossiﬁcation occurs in
the embryo [6]. There are two recognized processes occurring: the
induction of the peripheral bone (cortical) which will ultimately be
the load-bearing cylinder of a long bone, and the replacement of the
cartilage scaffold by internal bone and marrow. These two processes
match those required to enhance the integration of an implant (a
peripheral bone layer fused to the existing bone) and also the replace-
ment of a 3-D scaffold by bone. In order to replace a resorbable construct,
it must ﬁrst be invaded by angiogenic sprouts followed by the formation
of the bone collar around the periphery of the cartilage. Paracrine
hedgehog signaling is necessary for both of these events [7–10]. Manip-
ulation of this pathway is therefore a good target for the stimulation ofcense.
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the one molecule necessary for both these processes during embryo-
genesis, Indian hedgehog, neither part of the endochondral ossiﬁcation
occurs [7]. This process represents bone formation in trans – one cell
type induces the formation of another (cartilage inducing bone) – the
cells that give rise to the inducing signals (and extra-cellular matrix)
do not themselves produce the bone.
Previously, purmorphamine (Pur) that selectively induces osteogen-
esis in multipotent mesenchymal progenitor cells was identiﬁed [13].
Purmorphamine has been shown to increase alkaline phosphatase
(ALP) activity in both cell lines C3H10T1/2 andMC3T3-E1 and enhances
osteoblastic differentiation of human bone marrow mesenchymal cells
in culture and also when grown on titanium [14,15]. Further, it also
seems to inhibit adipocytematuration [16,17]. Purmorphamine induces
osteogenesis by activation of the hedgehog signaling pathway. The
transmembranic protein smoothened (Smo) is normally suppressed
by another transmembranic protein patched (Ptch); this suppression
is inhibited by sonic hedgehog protein in the developmental stage. It
has been shown that Smo can be artiﬁcially targeted by Pur and the sup-
pression by Ptch on Smo is stopped, leading to an activation of Smo and
thereby the hedgehog signaling pathway leading to stimulation of bone
formation. In this way Pur can replace the function of sonic hedgehog
(Fig. 1a) [18].
When the Smo inhibition is blocked by a hedgehog protein, Smo can
activate members of the Gli-family. Genetic studies have shown that
mutations in Gli2 and/or Gli3 result in severe defects in skeletal devel-
opment in mice and humans [19–22]. Ablating the hedgehog genes in
postnatal chondrocytes leads to dwarﬁsm, showing that the hedgehog
is essential for maintaining the growth plate and articular surface and
is required for sustaining trabecular bone and skeletal growth [23]. It
has been shown that Gli2 is a powerful transactivator of the BMP-2
gene in vitro and in vivo and that overexpression of Gli2 in osteoblast
precursor cells induces osteoblast differentiation [24]. This and the com-
bined effect of BMP-2 [25], explain the osteogenic induction by the
hedgehog pathway activation [26–28].
Themode of delivery of Pur is as important as the biology of its effect
as diffusion makes a simple injection ineffective. Delivering sonic
hedgehog or purmorphamine by binding it to a calcium phosphate
layer should stimulate differentiation and proliferation locally and spread
in a controlledmanner by the release of calcium phosphate. This delivery
system avoids the immediate burst-release of the active molecule and
allowing the osteogenesis of the surrounding precursor cells.
Calciumphosphate (CaP) is a natural component of the bone,making
a CaP or CaP coated delivery system ideal for the delivery of signal
molecules to enhance bone formation [29]. A CaP coating can be madeFig. 1. [a] Purmorphamine activates the hedgehog pathway by stimulating Smoothened instea
leads to more Gli expression, upregulating several other pathways including Wnt pathway, l
purmorphamine was administered to a similar degree as Dex and BMP-6, but following anoth
relative to Ct(GapdH), RQ; relative to dCt of Bsp of cells in negative medium (DMEM + 10%FCby sintering or in a biomimetic way, with the latter having the advantage
of being able to incorporate bioactive molecules into the coating without
destroying their biological activity. Since purmorphamine has never been
tested when adhered on an HA-coating, preliminary in vitro experiments
were performed in order to study if its ability to increase the Gli expres-
sion is maintained.
Some bone agonists have been implanted in ectopic sites to dem-
onstrate their osteogenic properties [30–32], but purmorphamine's
potential has not been tested, let alone delivered in an in vivo bone
defect. The assay system that was developed for this study, uses the
chorioallantoic membrane (CAM) of the chick to support the growth
and repair of explanted calvarial bone tissue [33]. This method shows
chondrocyte-derived agonists can stimulate the pathways involved in
endochondral bone formation and these agonists can be replaced by a
small molecule. The same assay is used to evaluate the integration
of an implant; the effect of a titanium coating and the addition of
purmorphamine are examined histologically and mechanically.Material and methods
Purmorphamine activity in medium and adhered onto CaP
Cells were isolated from the calvaria of neonatal mice (ICR-CD1,
Harlan, Oxon, UK) at P5, as previously described [34] based on the
original method [35]. In brief, sequential digests with crude Type IA
collagenase (Sigma, UK) were used on pooled calvaria (from 10 to
20pups), those cells being releasedﬁrstwere discarded and subsequent
fractions (up to 4) were collected and pooled. Cells were maintained
and expanded for a maximum of 2 passages and cultured in LG DMEM
(Invitrogen, Paisley, UK), 10% FBS (PAA, Farnborough, UK), p/s (PAA)
and ascorbate-2-phosphate (50 μg/ml; Fluka) (=negative medium).
Real-time Q-PCR analyses were used to check the upregulation of
the osteoblast differentiation marker Bsp after 1 and 2 weeks of
culture in neg. medium, pos. medium (=neg. medium + 10 mM
β-glycerophosphate (Invitrogen)), Dex (=pos. medium + 10−8 M
dexamethasone) [36–38], BMP-6 (=pos. medium + 100 ng/ml
BMP-6 (R&D Systems, UK)) [39,40], Pur (=pos. medium + 2 μM
purmorphamine (Calbiochem, Beeston, UK)) and Pur + BMP-6 (=pos.
medium + 2 μM purmorphamine + 100 ng/ml BMP-6). RNA was
extracted using Trizol (Invitrogen) according to the manufacturer's
guidelines; cDNA was prepared using a cDNA archive kit (Applied
Biosystems) and Q-OPCR was carried out according to the protocols for
theABI 7300Real-timePCRmachine in 96well formats. Taqmangene ex-
pression primer details were as follows: GapdH: Mm_99999915-g1; Bsp:d of inhibiting Patched which inhibits Smoothened like Sonic hedgehog protein does; this
eading to more bone formation; [b] RNA analysis showed the upregulation of Bsp when
er route as a combination of Pur and BMP-6 showed a synergistic effect; dCt = Ct values
S + p/s + Asc).
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relative expression software tool (REST) [41].
Calcium phosphate precipitation and purmorphamine adhesion
In the following in vitro tests, plastic Thermanox® coverslips (Nalge
Nunc Int., Naperville, IL, USA) coated with calcium phosphate were
compared to plain plastic of the 6 and 24-wells, following the method
suggested as a carrier for osteoinductive agents described by Liu et al.
[42]. The coverslips were cleaned in acetone, then in 70% ethanol, and
in demineralizedwater subsequently. Before being immersed in simulat-
ed bodyﬂuid (SBF: 142 mMNa+, 5 mM K, 1.5 mM Mg2+, 2.5 mMCa2+,
147.8 mMCl−, 4.2 mMHCO3−, 1.0 mMHPO42−, 0.5 mMSO42−usingNaCl,
NaHCO3, KCl, K2HPO4·3H2O, MgCl2·6H2O, CaCl2 and Na2SO4 (Sigma,
UK)) (5×) for 24 h at 37 °C, the pH had ﬁrst been adjusted to 6.5 by
the passage of gaseous carbon dioxide through the SBF (5×) [42]. The
slow rise of pH by the release of CO2 and the addition of Mg-molecules
stimulated the high nucleation precipitation of calcium phosphate on
the coverslips. After rinsing with PBS, a second coating was performed
in lower nucleation conditions using Hank's Balanced Salt Solution
HBSS with 3.5 mM CaCl2 added for 48 h at 37 °C. In this second slower
coating signal molecules can be added to incorporate them into the
Crystal lattice. Purmorphamine molecules were thereby adhered with
a simple heat immobilization procedure; after the CaP coating is
added, 1 ml of distilled water with 200 μM purmorphamine per disc
was allowed to evaporate on the surface by heating to 60 °C for several
hours.
Raman analysis of the CaP discs
A Raman spectrum of the CaP coated sample was obtained using a
LabRam spectrometer (Horiba Jobin Yvon, Stanmore, UK). This was
equipped with a 633 nm laser, grating of 1800 and ×50 objective.
Wavenumber range of 800 to 1650 cm−1, scan time of 5 s and sample
number of 20 were used. After smoothing and background subtraction
the sample spectra were comparedwith those obtained for hydroxyap-
atite and thermanox.
Light II reporter cells
Light II reporter cells (American Type Culture Collection, Manassas,
VA, USA) were cultured in DMEM with 4 mM L-Glutamine, 4.5 g/l
glucose, 1.5 g/l sodium bicarbonate supplemented with 0.4 mg/ml
G-418 (Autogen Bioclear, Calne, UK) and 0.15 mg/ml Zeocin (Autogen
Bioclear) and 10% fetal calf serum (PAA). G-418 was used to select for
the ﬁreﬂy and Zeocin for the Renilla luciferase reporter gene. After
being cultured to a maximal density, 10,000 cells/ml Light II cells
were seeded on plastic or on CaP discs using an assay DMEM-medium
supplemented with 0.5% fetal calf serum, 5 mM HEPES buffer (pH 7.4)
and the signal molecules if not already adhered on the CaP. To measure
activity of the adhered purmorphamine after release in the medium,
CaP coated discs with the agonist were put in DMEM for 24 h or 2×
24 h before the Light 2 cells were seeded onto them.
The cells growing on the CaP coated discs were visualized using ^^a
toluidine blue stain after ﬁxation in 4% PFA for 24 h and photographed
with a digital camera (Nikon Coolpix 4500) attached to a stereomicro-
scope (Zeiss Gmbh, Jena, Germany). To visualize the ability of cells to
attach onto the CaP surface and how this might inﬂuence the shape of
the cell, the discs were prepared for imaging by SEM. CaP coated discs
with adherent cells were ﬁxed in 3% glutaraldehyde in 0.1 M cacodylate
buffer (Agar Scientiﬁc Ltd., Stansted, Essex, UK) overnight and then
dehydrated through a series of ethanol solutions, 20%, 50%, 70%, 90%
and 3 changes in absolute ethanol. The discs were then placed for
2 min in Hexamethyldisilazane (Agar Scientiﬁc Ld, UK), removed and
allowed to dry. Theywere then attached to aluminium stubswith adhe-
sive carbon tabs (bothAgar Scientiﬁc Ltd, UK), sputter coatedwith gold/
palladium (Polaron E5OO, Bio-Rad, Richmond, Surrey UK) and viewed
in a JEOL JSM-5410LV SEM microscope (JEOL UK Ltd, Welwyn, Herts,
UK) operating at 10 kV and 10 mm working distance. SEM imageswould also reveal the roughness of the coating; which might inﬂuence
the cell's shape and ability to differentiate.
Dual ﬁreﬂy and Renilla luciferase Gli-reporter
After 48 h of growth on the test samples the cells were lysed
with Passive lysis buffer (Promega), the lysate was brought in a black
96-well and the Dual Luciferase Reporter™ assay was performed
using a Labsystems Luminoskan Ascent Plate Luminometer [43]. The
Gli-responsive ﬁreﬂy luciferase was measured manually and immedi-
ately after adding the Luciferase Assay Reagent II. Subsequently, the
Stop&Glo component was added to measure the constitutive Renilla
expression. A relative Gli expressionwas obtained by dividing theﬁreﬂy
by the Renilla luminescence.
In vivo agonist delivery by CaP in fetal chick femurs
Preparation of beads and adhesion of agonists
As described in Paul and Sharma, 1999; theHA-beadswere prepared
by mixing 5 g hydroxyapatite (Sigma-Aldrich, Dorset, UK) with 10 ml
of a 2% chitosan (Sigma) solution in 2% (v/v) acetic acid. The solution
was poured in sunﬂower-oil and stirred to dispense the chitosan-HA-
solution into small bubbles. The bifunctional cross-linking reagent
gluturaldehyde (Sigma) was added to cross-link the chitosan and the
formed beads were ﬁltered, washed with acetone and sintered at
1300 °C for 2 h. As the chitosan was burned away, pure porous
HA-beads were left over [44]. The beads were soaked in 200 μM
purmorphamine in PBS for 24 h and control beads were soaked in PBS
only; while this Pur concentration is 100× higher than the in vitro con-
centration tested itwas expected that the amountwould be sufﬁcient to
achieve a measurable effect.
In vivo implantation of the beads in a fetal chick femur defect
Fertilized eggs (J.K. Needle and Co., Herts, UK) were incubated at
39 °C within the ﬁrst week upon arrival. A host egg was windowed at
day 3 [45] to be able to use the chicken chorioallantoic membrane
(CAM) as a culture substrate at day 7. The femurs were isolated from
donor eggs at day 14. All soft tissues were removed from the femur
and a small defect was made with a tip of a needle (BD Microlance 3).
10 beads were taken with a micropipette and injected onto the defect
and pushed further into the defect with a needle-tip. This was
performed using beads soaked in purmorphamine and control beads
without purmorphamine (n = 3). The femur with the implant was
brought on the CAMof the host egg, thewindowwas sealedwith plastic
tape and the host eggwas incubated for another 7 days. In the following
experiments the femurs of the fetal chicken from the host egg could be
used as donors. All small animal experiments were carried out as
described in project license PPL 70/6269 by researchers with a personal
license (K. Gellynck: PIL 70/20356), both according to the Animals
(scientiﬁc procedures) Act 1986, Home Ofﬁce, UK.
Histology and analysis of the bone growth at the implant-site
After 7 days of further growth on the CAM the femurswere cut away
from the CAM and ﬁxed in 4% Paraformaldehyde (PFA) for 24 h. No
decalciﬁcation was done to leave the CaP beads intact; as the bone
was immature, the decalciﬁcation was not necessary. Subsequently to
an alcohol and xylene series the femurs were embedded in wax and
cut with a microtome (HM 330) at 8 μm. The sections were stained
with a 1% toluidine blue staining for 1 min. To be able to quantify the
difference in bone growth at the implant-site between the different
agonists and controls the Pro-Image-software (Pro-Image, Boulder,
CO, US) was used to calculate the percentage of bone marrow and
bone-less area towards the total bone area.
Bone marrow osteogenesis; alkaline phosphatase and mineralization
To clarify if the extra bone and bone cells could be bonemarrow de-
rived, the bone marrow of 18 day old chicken embryo femurs was
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changed into a negative medium (DMEM + 10%FCS + p/s + Asc), a
positive medium (negative + ß-glycerphosphate) and medium where
10−8 M dexamethasone, 100 ng/ml BMP-6, 0.1 M pamidronate
(Sigma Chemical Co, St Louis, USA) or 2 μM purmorphamine was
added. After 14 days of cell culturewith thesemedia, onewellwasmea-
sured for alkaline phosphatase activity using the standard PNPP assay
from Sigma. This develops a soluble yellow reaction product relative
to the amount of alkaline phosphatase measured at an absorbance of
410 nm; cells were lysed with 150 μl 1% Triton-X, 50 μl of the lysate
was added to 50 μl of the paranitrophenolphosphate (PNPP, Sigma)
assay buffer. The reaction was terminated after 30 min by the addition
of 150 μl 1 M NaOH. ALP activity was measured at 410 nm using the
Titertek Multiskan [46,47].
Stimulation of osseointegration
Ten 100 μm thick, 3 mm wide strips were cut coated from a PTFE
block. A titanium coating was added to 7 of them by Institut Straumann
AG (Basel, Switzerland) and 4 of these got an additional 200 μM
purmorphamine dried onto them. Similarly to the CaP bead implants,
these strips were pushed in a defect up to the bone marrow cavity of a
14 day old embryonic chick femur and placed on the CAM of a 7 day
old host egg for 7 days (Fig. 4a). The femurs were ﬁxed in 4% PFA and
immersed in LR white resin according to the manufacturer's protocol
and sectioned (10 μm) with a Reichert-Jung/Leica Polycut S microtome
(Heerbrugg, Switzerland). The trabecular bone was visible without
staining. To quantify the mechanical strength of the integration of the
PTFE strips, a metal hook was attached to the bottom clamp of the
dynamic mechanical analyzer (DMA, Perkin-Elmer) to hold the bone,Fig. 2. [a] Raman spectroscopy of the calcium phosphate precipitated sample; thermanox cove
hydroxyapatite, peak at 960 cm−1. Light 2 cells growing on precipitated CaP; toluidine blue sta
the CaP, relative to the cell number was measured using the Promega kit, and calculated by di
plastic (TCP) in medium (M) without purmorphamine (Pur) showed almost no expression; W
discs with 20 μM purmorphamine adhered onto it (CaP + pur), the cells showed a signiﬁcan
2 days before the cells were seeded onto them, the Gli expression became gradually smaller, busing the top clamp to pull the PTFE strip out of the bone (Fig. 4d). A
static force scan was performed using a constantly increasing force
(200 mN/min) until the strip (PTFE only n = 2, titanium coated PTFE
n = 3, titanium coated PTFE + purmorphamine n = 3) was pulled
out of the bone (breaking point) on which point the required force
was a quantiﬁcation for the integration.
Results
In vitro purmorphamine activity
The hedgehog pathway works over 2 transmembranic proteins;
patched (Ptch) and smoothened (Smo), where Smo is activating the
Gli protein function and transcription which will further regulate the
transcription of proteins important in bone formation like Wnt. In the
inactive state, Smo is inhibited by Ptch. The sonic hedgehog protein,
during bone formation in the developmental stage produced by
chondrocytes, will stop this inhibition and start bone formation
(Fig. 1a). Purmorphamine works by directly activating the Smo trans-
membrane protein regardless whether Ptch is inhibiting Smo or not.
This activationwas analyzed through the expression of the bonemarker
Bsp.
Q-PCR dCt values using GapdH as an internal control: in negative me-
dium (control): 1w: 14.17, 2W: 13.28; in positive medium: 1w: 13.53,
2W: 10.67; adding dexamethasone to positive medium: 1w: 12.14, 2W:
8.00; using BMP-6: 1w: 11.24, 2W: 8.14; using purmorphamine: 1w:
11.29, 2W: 7.21; using both purmorphamine and BMP-6: 1w: 8.51, 2W:
4.10. Thereby Q-PCR-data showed that the administration of 2 μM
purmorphamine had similar effect on the expression of Bsp as both dexa-
methasone and BMP-6. The upregulationwas greater thanwhen positiverslip; and hydroxyapatite; showed that the precipitated calcium phosphate was primarily
ined [b] and SEM picture [c]; scale bar: 10 μm. [d] The Gli expression in the Light 2 cells on
viding the ﬁreﬂy luminescence by the Renilla luminescence. Cells grown on tissue culture
hen cells were grown in medium with 2 μM purmorphamine (TCP-M + pur) or on CaP
tly higher expression. When these CaP + pur discs where presoaked in medium for 1 or
ut still higher than when no Pur was added onto the CaP.
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used without extra agonists. This activation by purmorphamine had an
additive effect compared to BMP-6 stimulation as the addition of both
simultaneously showed a higher upregulation than each on their own
(Fig. 1b). This shows that purmorphamine is a small molecule (=non-
protein molecule) that can activate the hedgehog pathway and thereby
stimulate bone formation.
Activity of purmorphamine adhered onto calcium phosphate coated discs
The strong Raman peak at 960 cm−1, (PO stretch) in the spectrum of
pure hydroxyapatite (dark blue spectrum, Fig. 2a)was clearly observed in
the Raman spectrum of the CaP coated plastic disc (light blue spectrum,
Fig. 2a), but not in the spectrum of the plastic disc without CaP (green
spectrum, Fig. 2a). Almost all other peaks from the CaP coated plastic
disc were coincident with and therefore attributed to Thermanox®
plastic peaks. Only a shoulder-peak around 1065 cm−1 was not identiﬁ-
able. This provides strong evidence that the biomimetically precipitated
CaP is primarily hydroxyapatite. Further analysis would be required to
conﬁrm purity but for our purpose as an agonist delivery mechanism
the veriﬁcation of the CaP coating is sufﬁcient (Fig. 2a). A Raman
spectrum of a coated disc with purmorphamine added did not
show any detectable differences compared to the spectrum of the
coated disc without purmorphamine. This is to be expected given
the low level of drug and conﬁrms this technique is not suitable for
quantifying Pur levels on the discs.
Whether the adhered small molecule kept its activity was analyzed
with a dual luciferase cell-based bioassay. As the Light 2 cells areFig. 3. CaP beads soaked in 200 μM purmorphamine for 24 h, were implanted in 14 day old em
kept alive for 7 days by grafting them onto the chorioallantoic membrane (cam) of a 7 day old
100 μm. These toluidine blue stained sectionswere used to calculate trabecular bone (tb)mass
parison [c] showed a signiﬁcant increase (48.25 +/− 6.52% to 68.19 +/− 7.13%) when purm
derived, the bone marrow of 18 day old chicken embryo femurs was ﬂushed out, and
(negative + ß-glycerphosphate) and positive medium plus dexamethasone, BMP-6, pamid
using the PNPP methodology showing that addition of ß-glycerphosphate, BMP-6 and purmo
creased and pamidronate even decreased the Alp activity.made to express ﬁreﬂy luciferase when the Gli-inducible promoter is
upregulated, the stimulation of thehedgehog pathway can be calculated
by measuring this ﬁreﬂy luciferase luminescence; the constitutive
Renilla luciferase is a measure for the number of cells (Figs. 2b and c
show the cell attachment and spreading onto the CaP coating). The
ratio of the two gives the Gli expression per cell, a quantiﬁcation of
the bio-activity of the adhered Pur. In Fig. 2d, it is shown that the cells
growing on the CaP coated discs with Pur expressed more luciferase
or Gli compared to those where no CaP was adhered. Soaking the Pur
CaP discs in medium once or twice for 24 h showed that not all of the
agonist molecules were released immediately but that there was a
gradual release up to 2 days and after soaking for 2 days the Gli expres-
sion was still being upregulated.
In vivo agonist delivery by CaP beads in fetal chick femurs
The size of theHA-porous beads (+/−30–150 μm)could be adjusted
by increasing the speed of the stirring, the faster the stirring; the smaller
the beads. A uniformity of the bead-size was not a necessity as beads
with a similar size (+/−50 μm) could be selected afterwards. The CaP
beads with an appropriate size could easily be pushed in the defect
with the tip of a 27 gage needle.
The chick femurs with the implants inserted were overgrown by
vessels from the chicken CAMand could thereby remain vital. The femurs
had even grown in thickness during the 7 days theywere on the CAM in-
cubated at 37 °C. During the sectioning of the middle part of the bone
care was taken to ensure that the bones were not over-decalciﬁed andbryonic chick femurs, empty control beads were implanted in others. These femurs were
host egg. [a] Shows the control bone and [b] where purmorphamine was added, scale bar:
by quantifying the percentage of trabecular bone using image-Pro Plus software. The com-
orphamine (Pur) was added to the beads. Showing this extra bone is bone marrow (bm)
cultured in negative medium (DMEM + 10%FCS + p/s + Asc), a positive medium
ronate or purmorphamine. After 14 days, alkaline phosphatase activity was measured
rphamine both increased the Alp activity signiﬁcantly, dexamethasone insigniﬁcantly in-
410 K. Gellynck et al. / Bone 57 (2013) 405–412the site of implant and the CaP beads could be retrieved. The toluidine
blue stained sections showed the difference in bone growth between
the controls and the femurs where beads with agonists had been
implanted (Figs. 3a and b). To quantify the bone growth the size of the
overall bone area, and the trabecular bone area were measured and the
proportion of trabecular bone area to the bone marrow was compared
between the different samples, the average 68.19 +/− 7.13% trabecular
bone to overall bone area of the test (Pur) samples was signiﬁcantly
higher than the 48.25 +/− 6.52% of the control samples, showing the
in vivo effect of the adhered small molecule in and on the implanted
CaP beads.
Bone marrow osteogenesis; alkaline phosphatase
The only selection from the bone marrow cell population was made
by removing the non-sticky cells when the medium was refreshed,
making it a rather stem-cell rich cell-mixture, similar to the bone
marrow. But a signiﬁcant increase in alkaline phosphatase activity
(this is a marker for osteodifferentiation of the cells) was seen when
BMP-6 (31.44 +/− 4.63) or Pur (31.27 +/− 5.86) was added to the
positive medium (7.37 +/− 2.07) as shown by the PNPP-spectroscopy
results in Fig. 3d; the addition of dexamethasone showed a small non-
signiﬁcant increase (9.10 +/− 0.81) and pamidronate even showed a
decrease (2.72 +/− 1.10) and was similar to the cells grown in negative
medium (2.97 +/− 1.41).
Stimulation of osseointegration
Even with the PTFE strips implanted in the embryonic femurs the
CAM was able to embed the bones and keep them alive for 7 more
days (Fig. 4a). Histology shows the presence of soft tissue in between
the space where the PTFE implant was and the trabecular boneFig. 4. To investigate the effect of a titanium coating +/− purmorphamine on osseointegration
coating (tcs), well or not soaked in 200 μMpurmorphamine were implanted through the bone
of a 7 day old host egg for 7 days. LR white resin was used tomake 10 μm sections: [b]; section
(tb) and implant (I). [c]; Section where a titanium coated PTFE strip with purmorphamine w
strength of the integrations, tensile tests [d] were performed on a dynamic mechanical analyze
time (or force) needed to pull the implant (I) out (=breaking) of the femur (f) held by a metal
themoment of breakingwhen the implantwas detached out of the femur. As a constantly increa
signiﬁcant difference was found between the PTFE controls (1.95 +/− 0.07 min) and the titaniu
and without purmorphamine (4.39 +/− 0.78 min) [f].(Fig. 4b), whereas with Ti coated and Ti coated Pur adhered strips the
trabecular bone was touching the implant on both sides (Fig. 4c). The
DMA tensile tests (Fig. 4d) showed that the constantly increasing
force only slightly moved the implant up to a breaking point when the
implant was pulled out of the femur (Fig. 4e). As a constantly increasing
force of 200 mN/min was applied, the time of breaking was a measure
of the force required to pull the implant out of the femur and as a
consequence the osseointegration of the implant. One PTFE implant
got detached during processing, illustrating its low strength. The aver-
age force required was lower for PTFE on its own compared to the Ti
coated strips, but no difference could be seen between the Ti coated im-
plants with or without purmorphamine (Fig. 4f).
Discussion
Calcium phosphate is already used frequently as a coating material
for bone implants showing good biocompatibility and bio-activity. It
also has been shown to increase the osteoconductivity and speed of
healing on implant placement [48]. The Raman spectra showed that
by precipitating CaP onto plastic discs, a hydroxyapatite-like calcium
phosphate coating could be formed. Using another method CaP beads
were produced. These beads can then be saturated with the small
molecules of interest and then be used as a vehicle for delivering
them to a site of bone damage.
The results, using light II cells, show that purmorphamine attached
to the CaP coating kept its activity and could activate the hedgehog
pathway for several days and that adhering or incorporating it to the
CaP surface attached cells can also be guided into the osteogenic differ-
entiation. These coated beads were used to deliver purmorphamine
in vivo in chicken embryo femur defects. Comparing the bone growth
showed that there is a signiﬁcant difference between the bone growth, 14 day old embryonic chick boneswere isolated and PTFE strips, with or without titanium
into the bonemarrow. Thewholewas embedded in a chorioallantoic membrane (cam, [a])
where a blank PTFE strip was implanted showing soft tissue (st) between trabecular bone
as implanted; the trabecular bone is touching the implant on both sides. To quantify the
r, a constantly increasing force was applied and set out against the position, showing the
hook (h) in the bottom clamp. A sharp incline in the position versus time graph [e] showed
sed force (200 mN/min)wasused, this time of breakingwas equivalent to a certain force. A
m coated strips (4.5 +/− 0.75 min), but not between the ones with (4.58 +/− 0.79 min)
411K. Gellynck et al. / Bone 57 (2013) 405–412at the implant-site of the beads soaked in agonists and the control
beads. This is the ﬁrst time the activity of purmorphamine is shown
in vivo; although there is already signiﬁcant research out there showing
the ability of this small molecule to induce osteogenic differentiation in
mesenchymal stem cells [49,50].
This research proved that purmorphamine can be delivered with
hydroxyapatite based biomaterials or that hydroxyapatite can be made
bioactive by soaking it in a purmorphamine solution. As the bonemarrow
was narrowed down by the delivered agonist it was questionable wheth-
er this was due to an overstimulation of the periosteum or whether this
extra bone formation could come from within the bone marrow or an
endosteal layer. As it was shown that bone marrow cells ﬂushed out of
the chicken embryo bones can be mineralized in vitro just as hMSC can,
it is possible that the extra bone formation is formed in this way.
The use of the chick femur model as a novel method to evaluate im-
plant integration is presented and showed the difference between PTFE
and titanium coated implants; but no difference in the strength of the
bone to implant bond was detected when the hedgehog agonist was
added. This could be explained by the possibility that purmorphamine
was not well enough taken up by the titanium or that the effect on the
integration was too small to be detected by the method used here. In
this method the bone-implant construct had to be transferred to the
mechanical analyzer and clamped and hooked using a self-made device.
This clamping can affect the construct, but once clamped the metal de-
vice will not bend compared to the bone-implant construct; hence all
movement and breaking is in the bone-implant construct. The results
from this study suggest that as purmorphamine is a cheap and stable
substitute for recombinant sonic hedgehog protein, it could be used in
bone regenerativemedicine, but it has not been shown to be an effective
adjunct to implant placement to enhance osseointegration.
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